Hematological toxicities of maintenance PARP inhibitors for patients with platinum-sensitive recurrent ovarian cancer

冯　征; 吴小华

doi:10.19401/j.cnki.1007-3639.2020.04.009

您当前的位置：

首页 >

文章列表页 >

Hematological toxicities of maintenance PARP inhibitors for patients with platinum-sensitive recurrent ovarian cancer

更新时间：2026-01-27

- Hematological toxicities of maintenance PARP inhibitors for patients with platinum-sensitive recurrent ovarian cancer
- China Oncology Vol. 30, Issue 4, Pages: 299-304(2020)
- 作者机构：
  
  复旦大学附属肿瘤医院妇瘤科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2020.04.009
  CLC： R737.31
- Published Online：12 May 2020，
  
  Published：12 May 2020
- 稿件说明：
移动端阅览
冯　征, 吴小华　. PARP抑制剂用于铂敏感复发卵巢癌患者维持治疗的血液学毒性概述[J]. 中国癌症杂志, 2020, 30(4): 299-304.

冯　征, 吴小华. Hematological toxicities of maintenance PARP inhibitors for patients with platinum-sensitive recurrent ovarian cancer[J]. China Oncology, 2020, 30(4): 299-304.
冯　征, 吴小华　. PARP抑制剂用于铂敏感复发卵巢癌患者维持治疗的血液学毒性概述[J]. 中国癌症杂志, 2020, 30(4): 299-304. DOI： 10.19401/j.cnki.1007-3639.2020.04.009.

冯　征, 吴小华. Hematological toxicities of maintenance PARP inhibitors for patients with platinum-sensitive recurrent ovarian cancer[J]. China Oncology, 2020, 30(4): 299-304. DOI： 10.19401/j.cnki.1007-3639.2020.04.009.

摘要

卵巢癌是威胁女性健康和生命的重大疾病之一。近年来，聚腺苷二磷酸核糖聚合酶抑制剂［poly (ADP-ribose)polymerase inhibitors，PARPi］作为一类新型的靶向治疗药物为卵巢癌患者带来获益，并被国内外多项临床指南、规范推荐用于铂敏感复发卵巢癌患者的维持治疗及术后的维持治疗。但与此同时带来的安全性问题，尤其是血液学毒性值得关注。从作用机制、药代动力学出发，对比目前已上市的3种PARPi的特征及其血液学毒性差异，以期为复发性卵巢癌患者临床用药提供参考。

Abstract

Ovarian cancer is one of the major health- and life-threatening diseases among females. In recent years

poly (ADP-ribose) polymerase inhibitors (PARPi)

as novel molecular-targeted therapy agents that bring benefits to ovarian cancer patients

have been recommended as maintenance therapy for platinum-sensitive recurrent ovarian cancer patients and postoperative maintenance therapy by several clinical guidelines. However

the safety issues

especially the hematological toxicities of the drugs

should be carefully regarded. This review compared the pharmacological characteristics and hematological toxicities of three different PARPi

so as to provide more information of the clinical application for the recurrent ovarian cancer patients.

关键词

Keywords

references

Views

3902

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Preliminary study on the role and mechanism of ISG15 in exosomes in platinum resistance in ovarian cancer

Progress in treatment of gynecological cancer in 2023

Progress in diagnosis and treatment of mucinous ovarian cancer

The latest progress and prospect of gynecological tumor treatment at 2023 ESMO

Progress in diagnosis and treatment of gynecological tumors in 2022

Related Author

Yanan TIAN

Hui ZHENG

Tianqing YAN

Heng ZHANG

Renquan LU

Lin GUO

Zheng FENG

Qinhao GUO

Related Institution

Department of Clinical Laboratory, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, State Key Laboratory of Genetic Engineering, Fudan University, Institute of Thoracic Oncology, Fudan University, Department of Oncology, Shanghai Medical College, Fudan University

Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, Fudan University

AI问答

⁰